Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates l-DOPA-Induced Dyskinesia in Aphakia Mice

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Molecular Neurobiology

• Publication date

  2018-09-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12035-018-1356-6PMID 30259400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.

  2018cited by this paper
• Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.

  2018cited by this paper
• Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3−/− Mice, a Genetic Model of Parkinson's Disease

  2018cited by this paper
• Dopamine receptors: homomeric and heteromeric complexes in l-DOPA-induced dyskinesia

  2018cited by this paper
• Selective remodeling of glutamatergic transmission to striatal cholinergic interneurons after dopamine depletion

  2017cited by this paper
• Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

  2017cited by this paper
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease

  2017cited by this paper
• Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.

  2017cited by this paper
• N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease

  2017cited by this paper
• Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.

  2016cited by this paper
• Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.

  2016cited by this paper
• L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum

  2016cited by this paper
• Mavoglurant in Parkinson's patients with l‐Dopa‐induced dyskinesias: Two randomized phase 2 studies

  2016cited by this paper
• A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease

  2016cited by this paper
• L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

  2016cited by this paper
• Association of Long-Term Nicotine Abstinence With Normal Metabotropic Glutamate Receptor-5 Binding.

  2016cited by this paper
• Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.

  2015cited by this paper
• Dopamine D3 Receptor Modulates l‐DOPA‐Induced Dyskinesia by Targeting D1 Receptor‐Mediated Striatal Signaling

  2015cited by this paper
• Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.

  2015cited by this paper
• Nicotinic ACh receptors as therapeutic targets in CNS disorders.

  2015cited by this paper
• Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

  2014cited by this paper
• Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.

  2014cited by this paper
• The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

  2014cited by this paper
• Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

  2014cited by this paper
• Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5

  2014cited by this paper
• AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.

  2014cited by this paper
• Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions

  2014cited by this paper
• L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.

  2014cited by this paper
• α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

  2013cited by this paper
• Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

  2013cited by this paper
• Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease

  2013cited by this paper
• Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.

  2012cited by this paper
• Is nicotine protective against Parkinson's disease? An experimental analysis.

  2012cited by this paper
• L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.

  2012cited by this paper
• Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography

  2012cited by this paper
• Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors

  2011cited by this paper
• Putaminal Upregulation of FosB/ΔFosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia

  2011cited by this paper
• Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

  2011cited by this paper
• Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.

  2011cited by this paper
• The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

  2011cited by this paper
• Molecular Mechanism for a Gateway Drug: Epigenetic Changes Initiated by Nicotine Prime Gene Expression by Cocaine

  2011cited by this paper
• Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

  2010cited by this paper
• Incentive Learning Underlying Cocaine-Seeking Requires mGluR5 Receptors Located on Dopamine D1 Receptor-Expressing Neurons

  2010cited by this paper
• Enhanced striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian mice

  2010cited by this paper
• A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.

  2010cited by this paper
• Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

  2009cited by this paper
• Intracellular Metabotropic Glutamate Receptor 5 (mGluR5) Activates Signaling Cascades Distinct from Cell Surface Counterparts*

  2009cited by this paper
• Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms

  2008cited by this paper
• Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.

  2008cited by this paper
• Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease

  2008cited by this paper
• ImageJ for microscopy.

  2007cited by this paper
• Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

  2007cited by this paper
• Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

  2007cited by this paper
• Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.

  2007cited by this paper
• Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease

  2007cited by this paper
• Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys

  2007cited by this paper
• ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

  2006cited by this paper
• 3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease

  2005cited by this paper
• Dysfunction of the cortico‐basal ganglia‐cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism

  2005cited by this paper
• Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6‐hydroxydopamine‐lesioned rats: Possible relevance to the effects of mGlu5R blockade in Parkinson's disease

  2005cited by this paper
• Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.

  2005cited by this paper
• Metabotropic glutamate receptors in the basal ganglia motor circuit

  2005cited by this paper
• Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.

  2002cited by this paper
• Effects of chronic nicotine administration on nitric oxide synthase expression and activity in rat brain

  2002cited by this paper
• Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.

  2001cited by this paper
• Modulation of nitric-oxide synthase by nicotine.

  2000cited by this paper
• Nicotine‐induced Protection Against Glutamate Cytotoxicity

  1996cited by this paper
• Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation.

  1996cited by this paper
• Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons

  1995cited by this paper
• Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.

  1993cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper

• A positive allosteric modulator of α7 nicotinic receptor reduces levodopa-induced dyskinesias in hemi-parkinsonian mice.

  2025cites this paper
• Future Perspectives of NMDAR in CNS Disorders

  2025cites this paper
• Pathological cell assembly dynamics in a striatal MSN network model

  2024cites this paper
• Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

  2023cites this paper
• Role of P11 through serotonergic and glutamatergic pathways in LID

  2023influential citation
• Striatal neuronal ensembles reveal differential actions of amantadine and clozapine to ameliorate mice L-DOPA-induced dyskinesia.

  2022cites this paper
• Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective

  2021cites this paper
• New Insights into Pathogenesis of L-DOPA-Induced Dyskinesia.

  2021cites this paper
• Loss of mGluR5 in D1 Receptor-Expressing Neurons Improves Stress Coping

  2021cites this paper
• Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner.

  2020cites this paper
• Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.

  2020cites this paper
• Dopamine D1 Receptors Regulate Spines in Striatal Direct‐Pathway and Indirect‐Pathway Neurons

  2020cites this paper
• Roles of Glutamate Receptors in Parkinson’s Disease

  2019cites this paper
• Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects

  2019cites this paper
• Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L‐DOPA in a mouse model of Parkinson's disease

  2019cites this paper
• Behavioral sensitization and cellular responses to psychostimulants are reduced in D2R knockout mice

  2019cites this paper
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease

  2017cites this paper